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providers in better understanding the needs of the caregivers, thereby, ensuring 
optimal outcomes for their patient.  
 
PND42  
MEASUREMENT OF HEALTH RELATED QUALITY OF LIFE USING EQ-5D IN 
PATIENTS WITH STROKE IN INDIA  
Marfatia S, Munshi S, Patel M 
pharmEDGE, Mumbai, India  
OBJECTIVES: To assess the impact of stroke on patient’s health related quality of 
life (HRQOL) using EQ-5D. METHODS: A convenient sample of 300 patients were 
recruited from six medical centers across three cities (Mumbai, Bangalore, and 
Delhi) in India. Patients older than 18 years diagnosed with stroke between June 
2011 to June 2012 who were receiving therapy for stroke were included in the 
study. Data on patients' socio-demographics, diagnosis, relevant clinical 
complications, were collected using a paper-based case report form. Patients 
were asked to rate their overall health using the EQ-VAS scale and data on the 
five dimensions of quality of life was collected using the EQ-5D questionnaire 
that was administered by trained interviewers. Translated and validated 
versions of the EQ-5D and EQ-VAS scales for five Indian languages were used in 
the study. RESULTS: The mean age of patients in the study was 58 (SD 14.45) and 
majority (70%) of the patients were males. Of the 300 patients, 60% had ischemic 
stroke. The mean EQ-VAS score was 66 (SD 23.09). Age and socioeconomic status 
were significant predictors (p<0.05, p<0.001 respectively) of EQ-VAS score. 
However, these variables were negatively correlated with the EQ-VAS score 
indicating that patients who were older and from an upper socioeconomic strata 
rated their overall health to be lower. Additionally, the frequency of problems 
was higher among older patients on mobility and usual care domains of the EQ-
5D scale than younger patients. CONCLUSIONS: These findings suggest the value 
of measuring health status among stroke patients in addition to assessing 
clinical symptoms as it enables comprehensive evaluation of a patient’s health 
condition.  
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OBJECTIVES: Type-1 Gaucher Disease (GD1) causes anemia, thrombocytopenia, 
hepatosplenomegaly, and skeletal pathology. Patients’ health-related quality of 
life (HRQoL) has been shown to be significantly diminished relative to the U.S. 
general population. Velaglucerase alfa is an enzyme replacement therapy (ERT) 
with the most comprehensive clinical trial registration program for an approved 
ERT in GD1 and has been reported as an effective and well-tolerated therapy. 
METHODS: The change in HRQoL, measured using the Short-Form-36 version 2 
(SF-36 v2) in adults at baseline and 1 year in a randomized, double-blinded, 
parallel-group, two-dose Phase III clinical trial of velaglucerase alfa, was 
designated a priori a non-key secondary endpoint. RESULTS: The mean baseline 
(SD) was 42.3 (8.00) and 46.0 (5.90) for the norm-based Physical Component 
Summary (PCS) and 41.7 (12.6) and 48.1 (10.7) for the norm-based Mental 
Component Summary (MCS), respectively, for the 45 U/kg (N=8) and 60 U/kg 
(N=7) treatment arms; the mean U.S. normal population score=50; 1 SD=10). 
Fourteen adult GD1 patients had completed both a baseline and 1 year SF-36 
HRQoL assessment (N=8 receiving 45 U/kg; N=6 receiving 60 U/kg). The respective 
mean change at 1 year [95% CI] for the PCS and MCS was 4.2 [-4.6, 13.0] and 4.1 
[1.0, 7.2] at the low dose and 1.7 [-3.9, 7.2] and 1.2 [-7.9, 10.3] at the high dose. 
Non-significant increases were observed in nearly all of the 8 individual SF-36 v2 
health domains compared to baseline, however, the mean increases, as well as 
the mean increases in the norm-based PCS and MCS summary measures, were 
aligned with the expected achievements of therapeutic goals for HRQoL. 
CONCLUSIONS: In addition to clinical efficacy and safety, velaglucerase alfa 
showed clinically important increases in HRQoL in adults as measured by the SF-
36 v2 within 1 year, however, further studies are needed.  
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CLINICAL AND ECONOMIC EVIDENCE THRESHOLDS FOR ORPHAN DRUGS: ARE 
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OBJECTIVES: Orphan drugs are therapies for low prevalence or neglected 
diseases with high unmet need. Many drugs have received orphan status 
globally, and benefited from 5-10 year marketing exclusivity; reduced 
stakeholder evidence requirements with unmet need weighing heavily into 
health technology assessment (HTA) and reimbursement decision-making; and 
largely uncontested pricing. Given tightening health system budgets, the 
proliferation of high priced orphan drugs in the United States (US) and Europe 
(EU) have caused these therapies to come under increased scrutiny from HTA 
agencies and payers to demonstrate value. To gain insight into evolving market 
access requirements, we conducted a multimarket review of orphan drug HTAs 
and reimbursement decisions comparing them to top selling non-orphan drugs 
in the US and EU. METHODS: Global HTAs and coverage decisions for orphan and 
blockbuster drugs were characterized and compared based on health economic, 
clinical and other value-based requirements. An analysis of orphan drug pricing 
was also conducted where pricing was available. RESULTS: More than 20 orphan 
drug HTAs were identified, including those for genetic and central nervous 
system disorders, cancer and cardiovascular disease. HTA agencies and payers 
scrutinized the robustness of clinical evidence and lack of comparator data. 
Cost-effectiveness was also often evaluated, though with relaxed ICER 
thresholds compared to non-orphan drugs. Failure of an orphan drug to meet 
historically accepted evidentiary thresholds have led some evaluators to grant 
conditional reimbursement, with the proviso that further supportive evidence 
must be provided, although outright reimbursement denial has become 
increasingly common. CONCLUSIONS: Once considered “reimbursement-safe” 
for drug developers, to achieve unrestricted reimbursement from payers orphan 
drugs now face higher evidentiary hurdles that are increasingly similar to non-
orphan drugs. New pharmaceuticals intent on achieving optimal market access 
as an orphan drug must factor the evolving requirements for demonstrating 
value into clinical and health economic evidence generation plans.  
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OBJECTIVES: To compare adherence rates, defined as the Medication Possession 
Ratio (MPR), for patients using alternative disease modifying therapies (DMTs)  
to treat multiple sclerosis (MS) that are enrolled in either a commercial 
insurance plan or through the Part D Medicare beneficiary program. METHODS: 
Study patients had >1 pharmacy DMT claim [interferon, glatiramer acetate (GA), 
fingolimod or natalizumab] and were enrolled in either a commercial health  
plan or Part D program between the dates of January 2010 and October 2012  
for patients using interferon, GA and natalizumab and between the dates of 
October 2010 and October 2012 for patients using fingolimod. Mean monthly MPR 
rates were calculated as the percentage of time the patient had access to a 
specific medication. RESULTS: The MPR for 243,330 and 197,784 commercial and 
Part D beneficiaries, respectively, were calculated across the study period. 
Adherence rates for commercial enrollees were similar across disease modifying 
therapies ranging from 75.4% for a once daily oral therapy to 79% for 
natalizumab. However, adherence in Medicare Part D beneficiaries was 
consistently lower than patients enrolled in commercial plans ranging from a 
reduction in MPR of 0.27% for GA to 7.4% in patients taking once daily oral 
fingolimod treatment. CONCLUSIONS: Medicare Part D beneficiaries had lower 
rates of adherence compared to MS patient enrolled in commercial plans which 
could present a unique opportunity for medication management programs 
offered either through pharmaceutical companies, health plans or specialty 
pharmacies.  
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OBJECTIVES: Neurologists care for chronic neurological illnesses through the use 
of disease-specific pharmacotherapies, but any licensed medical provider can 
prescribe these medications. Therefore, we evaluate effect of neurologist care on 
usage of disease-specific pharmacotherapies for chronic neurological diseases. 
METHODS: Survey respondents from the 2002-2010 Medical Expenditure Panel 
Survey(MEPS), an annual representative dataset of the civilian non-
institutionalized US population, were identified for multiple sclerosis, 
parkinsonism, epilepsy, and dementia. Data collection included prescription 
classes and sub classes (from Cerner Multum) for determining immuno-
modulatory, antiparkinsonian, anticonvulsant, and antidementia medications, 
identified neurologist ambulatory visits, age, illness duration, race, income, 
gender, education, comorbidities, region and year of care. Survey-weighted 
multivariate logistic and ordinary least squares regressions were performed on 
the outcomes of disease specific prescriptions and costs for the calendar year. 
Subgroup analyses were performed for each index condition. RESULTS: A total of 
4948 MEPS respondents (weighted sample: 5.1 million US citizens, 95% CI 4.8m-
5.4m) reported one or more index conditions. Only 27% reported a neurologist 
ambulatory care visit. Neurologist visits were associated with illness duration, 
high school graduate education, insurance coverage, and income. For the group 
seeing a neurologist, the adjusted likelihood of a patient with one of the four 
identified chronic neurological diseases receiving a disease-specific medication 
was substantially greater (OR 2.7, p-value <0.001) and adjusted annual 
expenditures for these medications was a mean of $1780 more (p-value <0.001); 
these estimates varied but were significant for all disease subgroups. 
CONCLUSIONS: Patients are much more likely to receive disease-specific 
pharmacotherapies for chronic neurological conditions when a neurologist is 
involved with their care. Policy makers and pharmaceutical companies should 
consider specialist physician involvement in care as a factor in determining the 
impact of new disease-specific medications.  
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